Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment

Fig. 2

a Tumor latency and volume plot. Mice were injected with RPMI8226 cells that had been pulsed for 24 h with either DMSO (n = 5) or 8 nM Bz (n = 5). Palpable tumors were observed in DMSO treated at day 28 (none in 8 nM Bz) and measurable at day 29. Tumors were measurable in 8 nM Bz mice at day 34 suggesting a 5-day latency period until tumor growth. *p = 0.0245 comparing DMSO to 8 nM Bz mice at day 34 (unpaired t test). b Tumor weight plot of U266 cells treated as in [A], excised on day 86 after injection. *p = 0.0322 (unpaired t test). Representative images of tumors at day of sacrifice. Tumors were in some cases excised with surrounding subcutaneous tissue. Dotted lines indicate the margins of the tumors determined as best as possible by visual inspection. c IHC detection of p21CIP1 levels in tumors derived from RPMI8226 and U266 cells pulsed for 24 h with DMSO or 8 nM Bz (n = 3). Quantification of percentage positive nuclear p21CIP1 in tumor sections. *p = 0.05 comparing DMSO vs. 8 nM Bz (unpaired t test). Scale bar =25 μm. Insets show details of p21 negative (DMSO) and positive (8 nM Bz) cells

Back to article page